PSMA-positive metastatic castration-resistant prostate cancer (MCRPC)

Clinical trials for PSMA-positive metastatic castration-resistant prostate cancer (MCRPC) explained in plain language.

Never miss a new study

Get alerted when new PSMA-positive metastatic castration-resistant prostate cancer (MCRPC) trials appear

Sign up with your email to follow new studies for PSMA-positive metastatic castration-resistant prostate cancer (MCRPC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 1 Not yet recruiting 2

Radioactive 'Smart Bomb' targets Hard-to-Treat prostate cancer

Disease control Recruiting now

This early-stage trial tests a new drug called 177Lu-PSMA-VG01 in men with a specific type of advanced prostate cancer (PSMA-positive mCRPC) that has spread and stopped responding to hormone therapy. The drug is designed to deliver radiation directly to cancer cells, aiming to sh…

Matched conditions: PSMA-POSITIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)

Phase 1 • Sponsor: VitsGen Therapeutics Inc. • Aim: Disease control

Last updated Jun 27, 2026 14:01 UTC

PSMA-positive metastatic castration-resistant prostate cancer (MCRPC)

Get alerted when new PSMA-positive metastatic castration-resistant prostate cancer (MCRPC) trials appear

Radioactive 'Smart Bomb' targets Hard-to-Treat prostate cancer